Neutralizing Antibody Escape during HIV-1 Mother-to-Child Transmission Involves Conformational Masking of Distal Epitopes in Envelope

ABSTRACT HIV-1 variants transmitted to infants are often resistant to maternal neutralizing antibodies (NAbs), suggesting that they have escaped maternal NAb pressure. To define the molecular basis of NAb escape that contributes to selection of transmitted variants, we analyzed 5 viruses from 2 mother-to-child transmission pairs, in which the infant virus, but not the maternal virus, was resistant to neutralization by maternal plasma near transmission. We generated chimeric viruses between maternal and infant envelope clones obtained near transmission and examined neutralization by maternal plasma. The molecular determinants of NAb escape were distinct, even when comparing two maternal variants to the transmitted infant virus within one pair, in which insertions in V4 of gp120 and substitutions in HR2 of gp41 conferred neutralization resistance. In another pair, deletions and substitutions in V1 to V3 conferred resistance, but neither V1/V2 nor V3 alone was sufficient. Although the sequence determinants of escape were distinct, all of them involved modifications of potential N-linked glycosylation sites. None of the regions that mediated escape were major linear targets of maternal NAbs because corresponding peptides failed to compete for neutralization. Instead, these regions disrupted multiple distal epitopes targeted by HIV-1-specific monoclonal antibodies, suggesting that escape from maternal NAbs occurred through conformational masking of distal epitopes. This strategy likely allows HIV-1 to utilize relatively limited changes in the envelope to preserve the ability to infect a new host while simultaneously evading multiple NAb specificities present in maternal plasma.

[1]  Pascal Poignard,et al.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.

[2]  D. Katzenstein,et al.  Maternal HIV‐1 Antibody and Vertical Transmission in Subtype C Virus Infection , 2002, Journal of acquired immune deficiency syndromes.

[3]  Bette T. Korber,et al.  Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.

[4]  E. Reinherz,et al.  Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface , 2009, Proceedings of the National Academy of Sciences.

[5]  E. Halapi,et al.  Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Lynn Morris,et al.  Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.

[7]  Tongqing Zhou,et al.  Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment , 2009, Journal of Virology.

[8]  Rajesh P. Ringe,et al.  Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies. , 2012, Virology.

[9]  L. Morris,et al.  The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.

[10]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[11]  M. Sagar HIV-1 transmission biology: selection and characteristics of infecting viruses. , 2010, The Journal of infectious diseases.

[12]  D. Thea,et al.  Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. , 1998, AIDS research and human retroviruses.

[13]  D. Venzon,et al.  Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. , 1995, The Journal of pediatrics.

[14]  H. Katinger,et al.  Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques , 2003, AIDS.

[15]  C. Chappey,et al.  Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission , 1995, Journal of virology.

[16]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[17]  A. Trkola,et al.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.

[18]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[19]  J. Sodroski,et al.  Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change , 1994, Journal of virology.

[20]  M. Reitz,et al.  An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. , 1993, Virology.

[21]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[22]  F. Bibollet-Ruche,et al.  Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.

[23]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Xiping Wei,et al.  Evidence for Potent Autologous Neutralizing Antibody Titers and Compact Envelopes in Early Infection with Subtype C Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[25]  E. Rosenberg,et al.  Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals , 2011, Journal of Virology.

[26]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[27]  Sriram Subramaniam,et al.  Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures , 2011, Proceedings of the National Academy of Sciences.

[28]  Maxim N. Artyomov,et al.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.

[29]  Marleen Temmerman,et al.  Diversity of the Human Immunodeficiency Virus Type 1 (HIV-1) env Sequence after Vertical Transmission in Mother-Child Pairs Infected with HIV-1 Subtype A , 2003, Journal of Virology.

[30]  Karina Yusim,et al.  Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants , 2006, Journal of Virology.

[31]  Charles Wood,et al.  Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. , 2002, AIDS research and human retroviruses.

[32]  Robert A. Rasmussen,et al.  Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge , 2001, Journal of Virology.

[33]  Joseph Sodroski,et al.  Stoichiometry of Antibody Neutralization of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.

[34]  M. Reitz,et al.  Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene , 1988, Cell.

[35]  J. Levy,et al.  Features of HIV-1 that could influence maternal-child transmission. , 1994, JAMA.

[36]  Hui Li,et al.  Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.

[37]  A. Perelson,et al.  A Signature in HIV-1 Envelope Leader Peptide Associated with Transition from Acute to Chronic Infection Impacts Envelope Processing and Infectivity , 2011, PloS one.

[38]  C. Blish,et al.  Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41 , 2008, PLoS medicine.

[39]  F. Onyango,et al.  Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. , 2000, JAMA.

[40]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[41]  Robyn L Stanfield,et al.  Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Reitz,et al.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope , 1990, Journal of virology.

[43]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.

[44]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[45]  J. Albert,et al.  Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.

[46]  B. Korber,et al.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. , 1992, Science.

[47]  J. Overbaugh,et al.  Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. , 2007, Current HIV research.

[48]  J. Overbaugh,et al.  HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. , 2002, AIDS research and human retroviruses.

[49]  O. Nishimura,et al.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Clapham,et al.  Genotypic and functional properties of early infant HIV-1 envelopes , 2011, Retrovirology.

[51]  Young Do Kwon,et al.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.

[52]  Hong Zhang,et al.  The Human Immunodeficiency Virus Type 1 Envelope Confers Higher Rates of Replicative Fitness to Perinatally Transmitted Viruses than to Nontransmitted Viruses , 2008, Journal of Virology.

[53]  A. West,et al.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10 , 2009, Proceedings of the National Academy of Sciences.

[54]  S. Lamers,et al.  Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo , 1993, Journal of virology.

[55]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[56]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[57]  G. Sapiro,et al.  Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.

[58]  Yan Liu,et al.  A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.

[59]  Susan Zolla-Pazner,et al.  A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex , 2000, Journal of Virology.

[60]  C. Kankasa,et al.  Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. , 2010, Virology.

[61]  L. Morris,et al.  Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop , 2011, Journal of Virology.

[62]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[63]  S. Zolla-Pazner,et al.  The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.

[64]  H. Katinger,et al.  Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1 , 2005, Journal of Virology.

[65]  Dorothy M. Lang,et al.  Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels , 2005, Journal of Virology.

[66]  J. Goudsmit,et al.  Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies , 1993, Journal of virology.

[67]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[68]  H. Katinger,et al.  The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.

[69]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[70]  S. Gnanakaran,et al.  Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways , 2009, PLoS pathogens.

[71]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[72]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[73]  F. Barin,et al.  Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties. , 2012, Virology.

[74]  A. Bartesaghi,et al.  Molecular Architectures of Trimeric SIV and HIV-1 Envelope Glycoproteins on Intact Viruses: Strain-Dependent Variation in Quaternary Structure , 2010, PLoS pathogens.

[75]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[76]  Huldrych F. Günthard,et al.  Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies , 2011, The Journal of experimental medicine.

[77]  Barbra A. Richardson,et al.  Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant , 2006, Journal of Virology.

[78]  Feng Gao,et al.  Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections , 2011, PLoS pathogens.

[79]  D. Montefiori,et al.  The Genetic Bottleneck in Vertical Transmission of Subtype C HIV-1 Is Not Driven by Selection of Especially Neutralization-Resistant Virus from the Maternal Viral Population , 2011, Journal of Virology.

[80]  Jerome H. Kim,et al.  Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.

[81]  C. Fundarò,et al.  Antibody‐dependent cellular cytotoxicity and neutralizing activity in sera of HIV‐1‐infected mothers and their children , 1993, Clinical and experimental immunology.

[82]  C. Blish,et al.  The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization. , 2011, Virology.

[83]  S. Spector,et al.  Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. , 1999, The Journal of infectious diseases.

[84]  Terri Wrin,et al.  Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies , 2009, Journal of Virology.

[85]  D. Nickle,et al.  Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope , 2005, Journal of Virology.